Want to see HK:2898 full AI Analyst Report?
2898 Stock Chart & Stats
HK$6.59
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$6.59
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$5.10 - HK$8.60
Previous CloseN/A
Volume4.80K
Average Volume (3M)9.77K
Market Cap
HK$970.43M
Enterprise ValueHK$761.38M
Total Cash (Recent Filing)HK$441.40M
Total Debt (Recent Filing)HK$68.24M
Price to Earnings (P/E)―
Beta-0.17
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding156,666,800
10 Day Avg. Volume6,180
30 Day Avg. Volume9,773
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.89
Price to Sales (P/S)11985.90
P/FCF Ratio-2.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageRelatively low reported debt-to-equity gives the company more financial flexibility to endure prolonged R&D cycles and pursue financing without immediate solvency pressure. Over 2–6 months, limited leverage reduces bankruptcy risk and preserves capacity to raise growth capital if needed.
Early Free Cash Flow ImprovementA modest uptick in free cash flow growth, even from a weak base, indicates the business may be beginning to stabilize cash conversion. If sustained, improving FCF can support working capital, fund late-stage development, and reduce dependence on dilutive financing over the medium term.
Access To Hong Kong Capital MarketsBeing listed on HKEX provides structural access to regional and international capital, enhancing options for follow-on financing and strategic partnerships. For a cash‑consuming biotech, this listing bolsters long-term fund-raising flexibility and investor reach versus unlisted peers.
Bears Say
Severe Revenue CollapseA ~98% revenue decline is a structural red flag: it erodes core cash generation, undermines commercial viability, and limits ability to fund operations and R&D internally. Over several months this magnifies funding needs and raises execution risk for product development and commercialization plans.
Deep Negative Margins And LossesPersistently negative operating and net margins indicate the business is not yet achieving scalable economics. Continued losses deplete equity, necessitate external capital, and can lead to repeated dilution, making it harder to achieve sustainable profitability without structural changes to the model.
Negative Cash Flow And Prior Negative EquityNegative operating and free cash flows combined with historical negative equity signal weak solvency and limited balance-sheet resilience. Over the medium term this constrains strategic choices, increases refinancing risk, and can force unfavorable financing or asset sales to bridge funding gaps.
Sunho Biologics,Inc. News
2898 FAQ
What was Sunho Biologics,Inc.’s price range in the past 12 months?
Sunho Biologics,Inc. lowest stock price was HK$5.10 and its highest was HK$8.60 in the past 12 months.
What is Sunho Biologics,Inc.’s market cap?
Sunho Biologics,Inc.’s market cap is HK$970.43M.
When is Sunho Biologics,Inc.’s upcoming earnings report date?
Sunho Biologics,Inc.’s upcoming earnings report date is Aug 28, 2026 which is in 23 days.
How were Sunho Biologics,Inc.’s earnings last quarter?
Currently, no data Available
Is Sunho Biologics,Inc. overvalued?
According to Wall Street analysts Sunho Biologics,Inc.’s price is currently Overvalued.
Does Sunho Biologics,Inc. pay dividends?
Sunho Biologics,Inc. does not currently pay dividends.
What is Sunho Biologics,Inc.’s EPS estimate?
Sunho Biologics,Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sunho Biologics,Inc. have?
Sunho Biologics,Inc. has 156,666,800 shares outstanding.
What happened to Sunho Biologics,Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Sunho Biologics,Inc.?
Currently, no hedge funds are holding shares in HK:2898
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sunho Biologics,Inc.
Sunho Biologics, Inc. is a biopharmaceutical firm dedicated to discovering, advancing, and bringing to market biological therapies. These treatments are designed to influence the body's immune system, both its inherent and adaptive responses, thereby altering the immune microenvironment. Among its portfolio is IAH0968, a monoclonal antibody specifically engineered to enhance antibody-dependent cell-mediated cytotoxicity, currently undergoing Phase II clinical trials for the treatment of biliary tract carcinoma and colorectal cancer. The company also develops IAP0971 and IAE0972, a pair of immunocytokines that have successfully concluded Phase I clinical trials for various advanced solid tumors, notably non-small cell lung cancer and colorectal cancer. Sunho Biologics also boasts a robust pipeline of early-stage assets. These include IBB0979, an immunocytokine targeting solid tumors; IBC0966, a dual-action fusion protein (anti-PD-L1 antibody-signal regulatory protein) in clinical development, designed to elicit tumor-specific immune responses; IBD0333, aimed at tumor cells; IAN0982, another oncology candidate; and immunosuppressants ISH0988 and ISH0613, which are being explored for autoimmune conditions. Established in 2018, the company operates from its headquarters in Huzhou, China, and functions as a subsidiary of Sunho Wisdom Investments Limited.
Technical Analysis
Genscript Biotech
―
Wuxi Biologics (Cayman)
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―